MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4...
Q1 2026
May 15, 2026
FY 2025
Mar 24, 2026
Q4 2025
Q3 2025
Dec 4, 2025
Q2 2025
Sep 19, 2025